Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.

@article{Ingwersen2012FingolimodIM,
  title={Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.},
  author={Jens Ingwersen and Orhan Aktas and Patrick K{\"u}ry and Bernd C. Kieseier and Alexey N. Boyko and H C Hartung},
  journal={Clinical immunology},
  year={2012},
  volume={142 1},
  pages={15-24}
}
Fingolimod, also known as FTY720, has recently been approved by the regulatory authorities in the US, EU, Australia, Russia, among others, for the treatment of relapsing-remitting multiple sclerosis. Fingolimod therefore represents the first oral drug for the treatment of this autoimmune disease of the central nervous system. Fingolimod modulates sphingosine-1 phosphate receptors and has unique immunoregulatory properties. Mechanistic studies from animal models have shown that fingolimod… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…